Clinical and Experimental Nephrology

, Volume 15, Issue 1, pp 50–57 | Cite as

CD28 superagonist-induced regulatory T cell expansion ameliorates mesangioproliferative glomerulonephritis in rats

  • Kenro Miyasato
  • Yoshitsugu Takabatake
  • Junya Kaimori
  • Tomonori Kimura
  • Harumi Kitamura
  • Hiroshi Kawachi
  • Xiao-Kang Li
  • Thomas Hünig
  • Shiro Takahara
  • Hiromi Rakugi
  • Yoshitaka IsakaEmail author
Original Article



Naturally occurring regulatory T cells (Treg) are essential for the prevention of autoimmunity and overshooting immune responses to pathogens; however, the involvement of Treg in mesangioproliferative glomerulonephritis, a major cause of chronic kidney disease, remains unclear. Superagonistic CD28-specific monoclonal antibodies (CD28SA) are highly effective activators of Treg in rats.


To confirm our hypothesis that CD28SA reduces the severity of experimental glomerulonephritis, anti-Thy1 nephritis model rats were treated with CD28SA or saline.


CD28SA significantly suppressed the increase in proteinuria and serum creatinine levels. CD28SA-treated nephritic rats exhibited an increase in the infiltration of Treg in the glomeruli accompanied by infiltration of CD163-positive macrophages (“alternatively activated” macrophages). In addition, CD28SA significantly induced interleukin-10 mRNA expression in glomeruli, thereby ameliorating mesangial cell proliferation and extracellular matrix expansion.


We established a new therapeutic approach to suppressing progressive glomerulonephritis. The therapeutic value of this approach warrants further attention and preclinical studies.


CD28 Regulatory T cell FoxP3 “Alternatively activated” macrophage 


  1. 1.
    Alpers CE, Hudkins KL, Gown AM, Johnson RJ. Enhanced expression of “muscle-specific” actin in glomerulonephritis. Kidney Int. 1992;41:1134–42.CrossRefPubMedGoogle Scholar
  2. 2.
    Striker LJ, Peten EP, Elliot SJ, Doi T, Striker GE. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest. 1991;64:446–56.PubMedGoogle Scholar
  3. 3.
    Mukai K, Shibata T, Kato K, Sugisaki T. Adjuvant-induced macrophage-dominant nephrotoxic serum nephritis in rats. Clin Exp Nephrol. 2005;9:15–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang XR, Tipping PG, Shuo L, Holdsworth SR. Th1 responsiveness to nephritogenic antigens determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int. 1997;51:94–103.CrossRefPubMedGoogle Scholar
  5. 5.
    El-Shemi AG, Fujinaka H, Matsuki A, Kamiie J, Kovalenko P, Qu Z, et al. Suppression of experimental crescentic glomerulonephritis by interleukin-10 gene transfer. Kidney Int. 2004;65:1280–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 2005;6:345–52.CrossRefGoogle Scholar
  7. 7.
    Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8–27.CrossRefPubMedGoogle Scholar
  8. 8.
    Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005;202:445–55.CrossRefPubMedGoogle Scholar
  9. 9.
    Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med. 2003;197:955–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Tacke M, Clark GJ, Dallman MJ, Hunig T. Cellular distribution and costimulatory function of rat CD28. Regulated expression during thymocyte maturation and induction of cyclosporin A sensitivity of costimulated T cell responses by phorbol ester. J Immunol. 1995;154:5121–7.PubMedGoogle Scholar
  11. 11.
    Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol. 2003;33:626–38.CrossRefPubMedGoogle Scholar
  12. 12.
    Kawachi H, Orikasa M, Matsui K, Iwanaga T, Toyabe S, Oite T, et al. Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen. Clin Exp Immunol. 1992;88:399–404.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamamoto T, Wilson CB. Complement dependence of antibody-induced mesangial cell injury in the rat. J Immunol. 1987;138:3758–65.PubMedGoogle Scholar
  14. 14.
    Takabatake Y, Isaka Y, Mizui M, Kawachi H, Shimizu F, Ito T, et al. Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther. 2005;12:965–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Azuma H, Isaka Y, Li X, Hunig T, Sakamoto T, Nohmi H, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant. 2008;8:2004–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.CrossRefPubMedGoogle Scholar
  17. 17.
    Mosser DM. The many faces of macrophage activation. J Leukoc Biol. 2003;73:209–12.CrossRefPubMedGoogle Scholar
  18. 18.
    Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005;105:4743–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Mahajan D, Wang Y, Qin X, Zheng G, Wang YM, Alexander SI, et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol. 2006;17:2731–41.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang YM, Zhang GY, Wang Y, Hu M, Wu H, Watson D, et al. Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. J Am Soc Nephrol. 2006;17:697–706.CrossRefPubMedGoogle Scholar
  21. 21.
    Wolf D, Hochegger K, Wolf AM, Rumpold HF, Gastl G, Tilg H, et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J Am Soc Nephrol. 2005;16:1360–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA. 2007;104:19446–51.CrossRefPubMedGoogle Scholar
  23. 23.
    Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523–32.CrossRefPubMedGoogle Scholar
  25. 25.
    Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2010

Authors and Affiliations

  • Kenro Miyasato
    • 1
  • Yoshitsugu Takabatake
    • 1
  • Junya Kaimori
    • 2
  • Tomonori Kimura
    • 1
  • Harumi Kitamura
    • 1
  • Hiroshi Kawachi
    • 3
  • Xiao-Kang Li
    • 4
  • Thomas Hünig
    • 5
  • Shiro Takahara
    • 2
  • Hiromi Rakugi
    • 1
  • Yoshitaka Isaka
    • 1
    Email author
  1. 1.Department of Geriatric Medicine and NephrologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Advanced Technology for TransplantationOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Department of Cell Biology, Institute of NephrologyNiigata University Graduate School of Medical and Dental SciencesNiigataJapan
  4. 4.Laboratory of Transplantation ImmunologyNational Research Institute for Child Health and DevelopmentTokyoJapan
  5. 5.Institut für Virologie and ImmunobiologieUniverstät WürzburgWürzburgGermany

Personalised recommendations